List view / Grid view
13 April 2016 | By Victoria White, Digital Content Producer
Results from the Phase IIb LUX-Lung 7 trial showed that afatinib significantly reduced the risk of lung cancer progression by 27% versus gefitinib...
8 April 2016 | By Victoria White, Digital Content Producer
A new study shows that levels of eosinophils can help identify patients with COPD who may and may not benefit from the addition of ICS treatment...
7 April 2016 | By Victoria White, Digital Content Producer
Afatinib is approved for the treatment of patients whose disease has progressed on or after treatment with platinum-based chemotherapy...
8 March 2016 | By Victoria White
The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype...
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
29 February 2016 | By Victoria White
The CHMP positive opinion is based on the results of the head-to-head LUX-Lung 8 trial in patients with SqCC...
29 February 2016 | By Victoria White
Boehringer Ingelheim's new initiatives are dedicated to raising awareness of IPF, a rare disease that is frequently misdiagnosed and little understood...
25 February 2016 | By Victoria White
Pooled analysis from the TOMORROW and INPULSIS trials provides further evidence that Ofev (nintedanib) significantly reduces the risk of acute exacerbations by 47% in people...
17 February 2016 | By Victoria White
Praxbind (idarucizumab) is now available to be used commercially after the Health Technology Appraisal bodies agreed that it is eligible for full reimbursment without the need for a full appraisal.
4 February 2016 | By Victoria White
Unlike other asthma daily maintenance treatments, Spiriva Respimat is from a new class of medications in asthma known as long-acting anticholinergics...
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
27 January 2016 | By Victoria White
Results from the LUX-Lung 7 trial demonstrated superiority in progression-free survival and time to treatment failure with Boehringer Ingelheim’s Giotrif/Gilotrif (afatinib) versus Iressa (gefitinib)...
26 January 2016 | By Victoria White
The FDA has accepted a sNDA for Jardiance (empagliflozin) based on cardiovascular risk reduction data from the EMPA-REG OUTCOME trial...
22 January 2016 | By Victoria White
The decision includes an update of the product information of all ambroxol and bromhexine containing products to include the rare risk of hypersensitivity reactions and a Precaution and Warning regarding severe cutaneous adverse reactions...
22 December 2015 | By Victoria White
The facility will produce ingredients manufactured using cell cultures and will create more than 400 new jobs in the Austrian capital...
